Trial reportJournal of the neurological sciences2012
Coenzyme Q10 deficiency in patients with Parkinson's disease.
Trial report in Journal of the neurological sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Association of Selenium Levels with Neurodegenerative Disease: A Systemic Review and Meta-Analysis.Nutrients · 2023Pooled it
- Association of the COQ2 V393A Variant with Parkinson's Disease: A Case-Control Study and Meta-Analysis.PloS one · 2015Pooled it
- Pooled it
- Ferroptosis and aging: Inducing and catalyzing neurodegenerative diseases.Neural regeneration research · 2026Article
- Ironing out mechanisms of ferroptotic death to tailor new stroke therapies.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026Review
- Hyperglycemia Aggravates 6-Hydroxydopamine-Induced Neuronal Ferroptosis via SLC7A11-Dependent Pathway in Diabetic PD Rat Model.CNS neuroscience & therapeutics · 2025Article
- Iron(ing) out parkinsonisms: The interplay of proteinopathy and ferroptosis in Parkinson's disease and tau-related parkinsonisms.Redox biology · 2025Review
- From pathogenesis to treatment: the emerging role of ferroptosis in Parkinson's disease.Frontiers in immunology · 2025Review
- Early diagnosis of Parkinson's disease: biomarker study.Frontiers in aging neuroscience · 2025Review
- Targeting Ferroptosis in Parkinson's Disease: Mechanisms and Emerging Therapeutic Strategies.International journal of molecular sciences · 2024Review
- New horizons for the role of selenium on cognitive function: advances and challenges.Metabolic brain disease · 2024Review
- Role of ferroptosis pathways in neuroinflammation and neurological disorders: From pathogenesis to treatment.Heliyon · 2024Review
- The Role of Calcium and Iron Homeostasis in Parkinson's Disease.Brain sciences · 2024Review
- Mapping the Research of Ferroptosis in Parkinson's Disease from 2013 to 2023: A Scientometric Review.Drug design, development and therapy · 2024Review
- From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology.International journal of molecular sciences · 2023Review
- Transferrin, insulin, and progesterone modulate intracellular concentrations of coenzyme Q and cholesterol, products of the mevalonate pathway, in undifferentiated PC12 cells.Journal of clinical biochemistry and nutrition · 2023Article
- Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research.Metabolic brain disease · 2023Review
- Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases.Biochemistry research international · 2023Review
- Exploring the Role of Lipid-Binding Proteins and Oxidative Stress in Neurodegenerative Disorders: A Focus on the Neuroprotective Effects of Nutraceutical Supplementation and Physical Exercise.Antioxidants (Basel, Switzerland) · 2022Review
- Cellular level of coenzyme Q increases with neuronal differentiation, playing an important role in neural elongations.Journal of clinical biochemistry and nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
unlabelledReactive oxygen species (ROS) are well known to contribute to the pathophysiology of Parkinson's disease (PD). Clinical trials of antioxidants are currently underway in PD patients, however, antioxidant research has been hindered by a lack of peripheral biomarkers.
methodsTwenty-two patients with PD elected to have a novel antioxidant assessment (Functional Intracellular Assay (FIA), SpectraCell Lab, Houston, TX) performed between 2004 and 2008. Each PD case was compared to four age- and gender-matched controls (n=88) in four separate, random iterations using laboratory data submitted during the same time period. Logistic regression was used to determine the odds of functional deficiency in antioxidant nutrients (i.e., glutathione, coenzyme Q10, selenium, vitamin E and alpha-lipoic acid) by case-control status. The proportion of cases with functional deficiency was also compared to that for controls by chi(2) test.
resultsCompared to cases, PD patients had a significantly greater odds of deficiency in coenzyme Q10 status (OR: 4.7-5.4; 95% CI: 1.5-17.7; P=0.003-0.009) based on FIA results, but not of vitamin E, selenium, lipoic acid, or glutathione (all P>0.05). The proportion of cases with coenzyme Q10 deficiency was also significantly greater in cases than in controls (32-36% vs. 8-9%; P=0.0012-0.006).
conclusionsDeficiency of coenzyme Q10 assessed via FIA should be explored as a potential peripheral biomarker of antioxidant status in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.